Journey Medical Corp. (DERM) Monday announced FDA's acceptance of its New Drug Application for DFD-29 or Minocycline Hydrochloride Modified Release Capsules, 40 mg for the treatment of inflammatory lesions and erythema of rosacea in adults. The Prescription Drug User Fee Act goal will be November 4, 2024.
Rosacea is an inflammatory skin condition that causes small, red, pus-filled bumps, redness and visible blood vessels in the face.
In the pre-market session, the shares are at $3.71, up 9.12 percent from the previous close of $3.40.
The commercial-stage pharmaceutical company said, if approved, DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea.
The company said the NDA submission was supported by positive data from its two DFD-29 Phase 3 clinical trials. The Phase 3 clinical trials achieved all co-primary and secondary endpoints. While evaluating erythema or redness associated with rosacea, one of the secondary endpoint, DFD-29 showed a statistically significant reduction in Clinician's Erythema Assessment compared to placebo.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.